# Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-plus-ipilimumab-or-placebo-for-metastatic-non-small-cell-lung/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael Boyer,Mehmet Alı Nahıt Şendur,Delvys Rodríguez‐Abreu,Keunchil Park,Dae Ho Lee,İrfan Çiçin,Perran Fulden Yumuk,Francesco Orlandi,Ticiana Leal,Olivier Molinier,Nopadol Soparattanapaisarn,Adrian Langleben,Raffaele Califano,Balazs Medgyasszay,Te‐Chun Hsia,Gregory A. Otterson,Lu Xu,Bilal Piperdi,Ayman Samkari,Martin Reck,for the KEYNOTE-598 Investigators |
| Citations | 256 |
| DOI | 10.1200/jco.20.03579 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.03579 |
| OpenAlex ID | https://openalex.org/W3124587416 |
| PMID | 33513313 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Te‐Chun Hsia](https://scholariq.org/researchers/te-chun-hsia/)
- [Keunchil Park](https://scholariq.org/researchers/keunchil-park/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.